The Journal of urology · 2003
Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Adachi Hiroyuki, Igawa Mikio, Shiina Hiroaki, Urakami Shinji, Shigeno Kazushi, Hino Okio
Аннотация
PURPOSE: Because loss of chromosome 9 is known to be the most common finding in human bladder tumors, we studied the mutation of the tumor suppressor gene TSC1 (chromosome 9q34) in bladder tumors. Since another tumor suppressor gene, TSC2 (chromosome 16p13.3), is reported to interact with TSC1 in the pathway that modulates tumor suppression, we assessed loss of heterozygosity (LOH) at 16p13.3. Furthermore, we also examined the expression of p27 because the TSC1 product is reported to influence the level of p27.
MATERIALS AND METHODS: Microsatellite markers were used to evaluate LOH at 9q34 or 16p13.3. Mutations of TSC1 were screened by single strand conformation polymorphism analysis and verified by direct sequencing. The expression of p27 was examined by reverse transcriptase-polymerase chain reaction and immunohistochemical examination.
RESULTS: We identified LOH at 9q34 in 12 of 37 bladder tumors (32.4%) but no LOH at 16p13.3 was observed. Furthermore, on single strand conformational polymorphism analysis we identified tumor specific mutations of TSC1 in 4 cases, of which all had LOH at 9q34, demonstrating the 2-hit mutations of TSC1. The expression of p27 was suppressed in all 4 cases with the 2-hit mutations of TSC1. Unexpectedly p27 suppression was detected at the transcription level, although its mechanism is unknown.
CONCLUSIONS: Our data suggest that the TSC1 mutation possibly has a causative role in the initiation or progression of some bladder tumors and this process is possibly related to the functional loss of p27.
MATERIALS AND METHODS: Microsatellite markers were used to evaluate LOH at 9q34 or 16p13.3. Mutations of TSC1 were screened by single strand conformation polymorphism analysis and verified by direct sequencing. The expression of p27 was examined by reverse transcriptase-polymerase chain reaction and immunohistochemical examination.
RESULTS: We identified LOH at 9q34 in 12 of 37 bladder tumors (32.4%) but no LOH at 16p13.3 was observed. Furthermore, on single strand conformational polymorphism analysis we identified tumor specific mutations of TSC1 in 4 cases, of which all had LOH at 9q34, demonstrating the 2-hit mutations of TSC1. The expression of p27 was suppressed in all 4 cases with the 2-hit mutations of TSC1. Unexpectedly p27 suppression was detected at the transcription level, although its mechanism is unknown.
CONCLUSIONS: Our data suggest that the TSC1 mutation possibly has a causative role in the initiation or progression of some bladder tumors and this process is possibly related to the functional loss of p27.
Предметные рубрики MeSH
Carcinoma, Transitional CellCell Cycle ProteinsCyclin-Dependent Kinase Inhibitor p27Cyclin-Dependent KinasesGene SilencingGenes, Tumor SuppressorHumansImmunohistochemistryLoss of HeterozygosityMicrosatellite RepeatsMutationPolymorphism, Single-Stranded ConformationalProteinsRepressor ProteinsReverse Transcriptase Polymerase Chain ReactionTuberous Sclerosis Complex 1 ProteinTuberous Sclerosis Complex 2 ProteinTumor Suppressor ProteinsUrinary Bladder Neoplasms